Semaglutide reduced HbA1c and body weight over 26 weeks in individuals with schizophrenia spectrum disorders and early glycemic abnormalities taking clozapine or olanzapine.
Question Can adjunctive semaglutide improve glycemic control and weight outcomes in individuals with early-stage prediabetes or diabetes and schizophrenia spectrum disorders who initiated clozapine or olanzapine within the past 5 years?
Findings In this randomized clinical trial including 73 participants, semaglutide was found to significantly reduce hemoglobin A1c level and body weight over a 26-week period. Approximately one-half of individuals treated with semaglutide achieved low-risk hemoglobin A1c levels, compared with the placebo group.
Meaning This study found that semaglutide can mitigate the early metabolic burden associated with second-generation antipsychotic use in schizophrenia and may support the prevention of long-term cardiometabolic complications when initiated during the early stages of metabolic dysregulation.